title: Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients.
abstract: Parainfluenza virus (PIV) infections can cause serious respiratory infections and death in immunocompromised patients. No antiviral agents have proven efficacy against PIV, and therapy generally consists of supportive care. DAS181, a novel sialidase fusion protein that temporarily disables airway epithelial PIV receptors by enzymatic removal of sialic acid moieties, has been shown to inhibit infection with PIV strains in vitro and in an animal model. We describe here the clinical course of 2 immunocompromised patients with PIV-3 infection, one with a history of lung transplantation and the other neutropenic after autologous hematopoietic stem cell transplantation for multiple myeloma. Both patients had substantial clinical improvement in respiratory and systemic symptoms after a 5-day DAS181 treatment course, although the clinical improvement in the autologous stem cell transplantation patient also paralleled neutrophil engraftment.
authors.affiliation: Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
authors.forename: B B
authors.initials: BB
authors.lastname: Guzmán-Suarez
authors.forename: M W
authors.initials: MW
authors.lastname: Buckley
authors.forename: E T
authors.initials: ET
authors.lastname: Gilmore
authors.forename: E
authors.initials: E
authors.lastname: Vocca
authors.forename: R
authors.initials: R
authors.lastname: Moss
authors.forename: F M
authors.initials: FM
authors.lastname: Marty
authors.forename: R
authors.initials: R
authors.lastname: Sanders
authors.forename: L R
authors.initials: LR
authors.lastname: Baden
authors.forename: D
authors.initials: D
authors.lastname: Wurtman
authors.forename: N C
authors.initials: NC
authors.lastname: Issa
authors.forename: F
authors.initials: F
authors.lastname: Fang
authors.forename: S
authors.initials: S
authors.lastname: Koo
mesh_terms: D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010224:Parainfluenza Virus 3, Human / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D018184:Paramyxoviridae Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D011993:Recombinant Fusion Proteins; C525612:oplunofusp